An Observational Study Of Safety Of Sacubitril And Valsartan Combination In Patients Of Heart Failure With Reduced Ejection Fraction In Medicine Department Of Sawai man singh Hospital, Jaipur - NIL

开始日期2024-09-15

申办/合作机构-

NCT06266988

/ Not yet recruiting临床1期

A Bioequivalence Study of Two Formulations of Sacubitril/Valsartan 97 mg/103 mg Film-coated Tablets in Healthy Thai Subjects Under Fasting Conditions

Primary objective is to is to evaluate the bioequivalence of two formulations

开始日期2024-03-01

申办/合作机构

Viatris, Inc.

NCT05848206

/ CompletedN/A

Impact of Formulary Coverage of Entresto (Sacubitril/Valsartan) on Prescription Abandonment/Rejection and Subsequent Treatment and Economic Outcomes in Chronic Heart Failure Patients in the U.S.

This was a retrospective cohort study utilizing IQVIA open-source pharmacy and medical claims data among patients with a sacubitril/valsartan (SAC/VAL) prescription transaction.

开始日期2022-03-11

申办/合作机构

Novartis Pharmaceuticals Canada, Inc.

100 项与沙库巴曲相关的临床结果

登录后查看更多信息

100 项与沙库巴曲相关的转化医学

登录后查看更多信息

100 项与沙库巴曲相关的专利（医药）

登录后查看更多信息

2,297

项与沙库巴曲相关的文献（医药）

2025-11-01·AMERICAN HEART JOURNAL

Structural abnormalities and effects of sacubitril/valsartan in patients with mildly reduced or preserved ejection fraction and worsening heart failure: The PARAGLIDE-HF trial

Article

作者: Kittipibul, Veraprapas ; Cyr, Derek D ; Harrington, Josephine ; Ward, Jonathan H ; Sarwat, Samiha ; Fudim, Marat ; Lala, Anuradha ; Solomon, Scott D ; Starling, Randall C ; Zieroth, Shelley ; Mentz, Robert J ; Hernandez, Adrian F

BACKGROUND:

PARAGLIDE-HF showed significantly greater reduction in NT-proBNP in patients with LVEF>40% and worsening HF with sacubitril/valsartan (sac/val) vs valsartan (val). The impact of structural abnormalities on the effects of sac/val in this context is unknown. This study aimed to evaluate the impact of left ventricular hypertrophy (LVH) and left atrial enlargement (LAE) on sac/val in patients with LVEF>40% and worsening HF.

METHODS:

PARAGLIDE-HF patients were classified into 3 groups according the degree of structural abnormalities using LVH and LAE. The primary endpoint was time-averaged proportional change in NT-proBNP from baseline to Weeks 4 and 8. Secondary endpoints were recurrent cardiovascular composite events (HF hospitalizations, urgent HF visits, cardiovascular death) and adverse events (symptomatic hypotension, hyperkalemia, worsening renal function).

RESULTS:

Of 454 (97.4%) patients with LVH and LAE data, 157 (34.5%) had both LVH and LAE, 178 (39.2%) had either LVH or LAE, and 119 (26.2%) had neither LVH nor LAE. Greater reduction in NT-proBNP with sac/val vs val was consistent across groups (P interaction = 0.705). There was no significant interaction between treatment and degree of structural abnormalities for other efficacy endpoints. Patients with both LVH and LAE had significantly higher odds of hyperkalemia with sac/val (OR 2.41, P interaction = 0.024).

CONCLUSION:

Patients with LVEF>40% and recent WHF had greater reduction in NT-proBNP with sac/val vs val, regardless of the degree of structural abnormalities. There was no difference in the effects of sac/val on efficacy endpoints across structural abnormality group. Patients with both LVH and LAE had higher odds for hyperkalemia with sac/val.

2025-11-01·AMERICAN HEART JOURNAL

Influence of ejection fraction on outcomes with sacubitril/valsartan in patients with worsening heart failure with EF>40%: The PARAGLIDE-HF Trial

Article

作者: Zieroth, Shelley ; Ward, Jonathan H ; Mentz, Robert J ; Fudim, Marat ; Peters, Anthony E ; Cyr, Derek ; Williamson, Kristin M ; Li, Shuang

BACKGROUND:

In the PARAGLIDE-HF trial, treatment with sacubitril/valsartan (Sac/Val) was associated with greater reduction in NT-proBNP than valsartan (Val) alone in patients stabilized after an episode of worsening heart failure (HF) with left ventricular ejection fraction (LVEF) >40%. Treatment effects were most apparent in the subgroup with LVEF below normal (≤60%). This prespecified analysis sought to compare the detailed treatment effects and adverse event profiles of Sac/Val vs Val in patients with LVEF ≤60% vs >60%.

METHODS:

Baseline demographics and clinical characteristics were compared between patients with baseline LVEF ≤60% vs >60%. Rates of recurrent composite events (adjudicated CV death, HF hospitalizations, and urgent HF visits) were compared between groups using a semi-parametric proportional rates model. These recurrent composite events were also analyzed across the continuous LVEF spectrum using restricted cubic splines. Incidence of adverse events were analyzed using a logistic regression model with LVEF ≤60% vs >60%, treatment arm, and in-hospital/out-of-hospital randomization as covariates. The interaction of LVEF category and treatment arm was assessed for all models RESULTS: Compared to those with LVEF >60%, patients with LVEF ≤60% were younger with lower NYHA class, but similar NT-proBNP values at baseline and similar co-morbidity burden. Among patients with LVEF ≤60%, those treated with Sac/Val experienced fewer recurrent composite events compared to those treated with Val (rate ratio 0.60 [95% CI: 0.37-0.99], P = .046); predominantly driven by HF hospitalizations. Patients with LVEF >60% treated with Sac/Val vs Val demonstrated similar rates of recurrent composite events (RR 1.46 [0.77-2.79], P = .24) (interaction P-value = .032). This was consistent with the continuous analysis in which patients treated with Sac/Val were significantly less likely to have events compared with patients with Val at LVEF values below 58%. Patients with LVEF >60% treated with Sac/Val experienced more symptomatic hypotension (OR 3.55 [95% CI: 1.35-9.37], P = .01) compared to those treated with Val, whereas rates of symptomatic hypotension were comparable across treatment groups in patients with LVEF ≤60% (OR 1.36 [0.79-2.32], P = .27, interaction P-value .09).

CONCLUSIONS:

Compared to treatment with Val in patients with worsening HF and LVEF >40%, treatment with Sac/Val is associated with greater clinical benefit in those with LVEF ≤60% than in those with LVEF >60%.

CLINICAL TRIAL REGISTRATION:

Clinicaltrials.gov identifier, NCT03988634.

2025-10-01·AMERICAN HEART JOURNAL

Effects of angiotensin-neprilysin inhibition in women vs men: Insights from PARAGLIDE-HF

Article

作者: Hernandez, Adrian ; Starling, Randall ; Erickson, Tyler ; Morrow, David ; Solomon, Scott ; Rambarat, Paula ; Mentz, Robert ; Velazquez, Eric ; Ward, Jonathan ; Zieroth, Shelley ; Williamson, Kristin ; Cyr, Derek

BACKGROUND:

Sub-analyses of key trials suggest a preferential benefit for specific heart failure with preserved ejection fraction (HFpEF) therapies in women. This work investigated treatment effects between women and men in the PARAGLIDE-HF (Prospective comparison of ARNI with ARB Given following stabiLization In DEcompensated HFpEF) trial.

METHODS:

In this prespecified subgroup analysis, we examined outcomes according to sex in the PARAGLIDE-HF trial. The primary endpoint was time-average proportional change in amino terminal pro-B type natriuretic peptide (NT-proBNP) from baseline through Weeks 4 and 8. We also examined secondary outcomes and tolerability.

RESULTS:

Overall, 242 women (52%) and 224 men (48%) were randomized. Women had significantly higher LVEF, worse renal function, and less comorbidities than men. In the overall population, the time-averaged reduction in NT-proBNP was significantly greater for sacubitril/valsartan (sac/val) than valsartan (ratio of change 0.85, 95% CI, 0.73-0.999). When examined according to sex, the time-averaged reduction in NT-proBNP was numerically greater with sac/val in both women (ratio of change = 0.86, 95% CI, 0.69-1.070) and men (ratio of change 0.84, 95% CI, 0.67-1.05) with no differential treatment effect (P interaction = .91). Similarly, the secondary hierarchical endpoint favored sac/val over valsartan in both women and men but was not statistically significant. Study drug dosage levels were similar across women and men and there were no sex-specific differences in the incidence of adverse events.

CONCLUSIONS:

In patients with mildly reduced or preserved EF >40% and a recent worsening HF event, the efficacy, safety and tolerability of sac/val vs valsartan were similar in both women and men, suggesting consistent effects across appropriately selected patients regardless of sex. Future prospective studies are needed to further evaluate sex-specific differences in treatment response of HFpEF therapies.

TRIAL REGISTRATION:

Prospective comparison of ARNI with ARB Given following stabiLization In DEcompensated HFpEF; NCT03988634; https://www.

CLINICALTRIALS:

gov/study/NCT03988634.

127

项与沙库巴曲相关的新闻（医药）

2025-08-19

·PRNewswire

MSN Marks Major Milestone with U.S. Launch of Sacubitril and Valsartan Tablets Following Hard-Fought Legal Victory

PISCATAWAY, N.J., Aug. 19, 2025 /PRNewswire/ -- MSN Pharmaceuticals, the U.S. subsidiary of global pharmaceutical leader MSN Group, is pleased to announce the launch of its generic Sacubitril+Valsartan Tablets in the United States, which is indicated to reduce the risk of cardiovascular death and hospitalization for adult patients with chronic heart failure and reduced ejection fraction. This marks a significant achievement in MSN's journey to expand access to affordable, high-quality cardiovascular medications for patients across the country. Sacubitril and Valsartan Tablets is an important combination therapy widely used in the management of chronic heart failure with reduced ejection fraction. It helps to reduce the risk of cardiovascular death and hospitalizations, offering hope and an improved quality of life to patients throughout the United States. MSN's path to launch was shaped by a rigorous legal and regulatory process. The company was at the forefront of a complex patent litigation that spanned multiple years. Despite facing multiple legal obstacles, including attempts to delay the approvals and launch of the product, MSN remained committed to its mission and engaged in a principled defence of its right to be first to introduce its cost effective generic product. Throughout this process, MSN Pharmaceuticals worked in close coordination with regulatory authorities and adhered to the highest standards of legal compliance and product quality. After multiple court hearings, temporary injunctions, and legal appeals, MSN ultimately secured the necessary approvals to bring its Sacubitril and Valsartan tablets to the U.S. market. "This launch stands as a symbol of our perseverance, integrity, and unwavering belief that lifesaving medicines must be accessible to all. Aligned with the U.S. government's vision and policy of promoting reduced drug prices through the promotion of robust generic pharmaceutical competition, this milestone reflects our enduring commitment to strengthening global healthcare access through our facilities in the USA as well" MSN Pharmaceuticals said in a statement. MSN Group is among the fastest-growing, fully integrated pharma companies with 25 state-of-the-art facilities in India and the USA. Its unified R&D drives both APIs and finished dosage research. With 1000+ patents, 200+ ANDAs, and the world's No.1 position in US DMF filings, MSN offers 500+ APIs and 400+ finished dosages across 35+ therapeutic areas, serving 50M+ patients in 100+ countries with speed, reliability, and trust. SOURCE MSN Pharmaceuticals WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

上市批准专利侵权

2025-08-18

·GlobeNewswire-Health Care

New Novartis ESC data highlights strength of cardiovascular portfolio

PRESS RELEASE Two VictORION studies will highlight Leqvio’s impact on patient quality of life, and as a cholesterol lowering monotherapyLp(a)FRONTIERS APHERESIS study will assess effect of pelacarsen on reducing need for lipoprotein apheresis – a cholesterol removal procedure similar to dialysisPARACHUTE-HF study will highlight the efficacy and safety of Entresto to treat heart failure with reduced ejection fraction due to chronic Chagas diseaseAdditional presentations will assess the safety of new pipeline asset abelacimab in atrial fibrillation Basel, August 18, 2025 – Novartis will present data from 19 abstracts across its cardiovascular portfolio at the 2025 European Society of Cardiology (ESC) Congress in Madrid from August 29 to September 1, 2025. “The latest data we are presenting at ESC will showcase how Novartis is pioneering groundbreaking treatments that can transform cardiovascular outcomes,” said Ruchira Glaser, M.D., Global Head, Cardiovascular, Renal and Metabolic Development Unit, Novartis. “With established treatments Entresto and Leqvio, we continue to explore new ways to improve patient care whilst also investigating broader populations who may benefit. With promising pipeline assets, pelacarsen and abelacimab, we are tackling areas of significant unmet need to address the myriad of factors that cause or worsen heart disease.” Key highlights of data accepted by ESC include: Medicine Presentation Title Presentation Details Pelacarsen Pelacarsen reduces the need for lipoprotein apheresis in patients with elevated lipoprotein(a) and cardiovascular disease: The Phase 3 Lp(a)FRONTIERS APHERESIS trial Station 12 (Research Gateway) Moderated ePoster August 29, 09:15-10:00 CEST Pelacarsen Association of elevated lipoprotein(a) with future major adverse cardiovascular events in recurrent ASCVD patients: analysis of a large US electronic health record database Station 2 (Research Gateway) Moderated ePoster August 30, 17:15 – 18:00 CEST Pelacarsen Economic burden of elevated lipoprotein(a) in secondary prevention of atherosclerotic cardiovascular disease cohort from England Discovery Pole (North Convention Centre) Poster August 29, 15:15 CEST Leqvio VICTORION-Difference study: Inclisiran-based strategy vs standard of care Madrid (Main Auditorium) Hot Line August 30, 17:00 CEST Leqvio VICTORION-Mono China: efficacy and safety of inclisiran as monotherapy in Chinese adults with low or moderate ASCVD risk and elevated LDL-C Discovery Pole (North Convention Centre) Poster August 29, 10:00 CEST Abelacimab Prior anticoagulation experience, bleeding risk, and safety of factor XI inhibition in atrial fibrillation: an analysis of AZALEA-TIMI 71 Science Box 3 (Research Gateway) Poster September 1, 14:30 CEST Abelacimab Renal function and factor XI inhibition in atrial fibrillation: a pre-specified analysis of AZALEA-TIMI 71 Science Box 3 (Research Gateway) Poster September 1, 15:00 CEST Entresto PARACHUTE-HF: Randomized trial comparing sacubitril/valsartan with enalapril in patients with HFrEF caused by chronic Chagas cardiomyopathy Madrid (Main Auditorium) Hot Line September 1, 8:15 CEST About Novartis in Cardiovascular DiseaseAt Novartis, our mission is to ensure no heart is lost too soon. We envision a world where preventable CV deaths are no longer part of our lives. We’re proud of the positive impact we’ve made over the past 40 years and remain dedicated to tackling the most challenging problems in CVD. Through cutting-edge science and technology, we are focusing on areas of high unmet need, including scaling our xRNA platform across multiple risk factors and pioneering breakthroughs for genetically driven CVD risk factors and common heart conditions, including atrial fibrillation. We also work with patients, healthcare professionals, and organizations around the world to improve CV care beyond medicine alone. Together, we can help people with CVD enjoy longer, healthier lives and more time with their loved ones. DisclaimerThis press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise. About Novartis Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide. Reimagine medicine with us: Visit us at https://www.novartis.com and connect with us on LinkedIn, Facebook, X/Twitter and Instagram. # # # Novartis Media RelationsE-mail: media.relations@novartis.com Novartis Investor RelationsCentral investor relations line: +41 61 324 7944E-mail: investor.relations@novartis.com

临床3期AHA会议

2025-08-14

·米内网

【关注】超49亿重磅品种，国药集团发起冲击

精彩内容近日，CDE官网显示，国药集团提交的4类仿制药沙库巴曲缬沙坦钠片、3类仿制药注射用硫酸多黏菌素B上市申请获受理。在中国三大终端六大市场（统计范围详见本文末），沙库巴曲缬沙坦钠片、注射用硫酸多黏菌素B销售额峰值分别超49亿元和18亿元。来源：CDE官网沙库巴曲缬沙坦钠片是由沙库巴曲（脑啡肽酶抑制剂）和缬沙坦（血管紧张素Ⅱ受体拮抗剂）组成的复方制剂，目前已纳入国家医保乙类药目录，限制使用范围：①射血分数降低的慢性心力衰竭成人患者；②原发性高血压。在中国三大终端六大市场，沙库巴曲缬沙坦钠片近年来销售额持续攀升，2024年拿下创新高的超49亿元；2025Q1继续以17.27%的增速增长至约15亿元，为高血压化药TOP1产品。目前该药已有27家企业（本土25家、进口2家）拥有生产批文，石药集团、正大天晴药业、国药集团等60余家企业以新分类提交上市申请，其中有26家已获批上市、视同过评。近年来中国三大终端六大市场沙库巴曲缬沙坦钠片销售趋势（单位：万元）来源：米内网格局数据库注射用硫酸多黏菌素B是一种从多黏芽孢杆菌中分离出的抗菌性多肽，可用于绿脓杆菌及其他假单胞菌引起的创面、尿路以及眼、耳、气管等部位感染，也可用于败血症、腹膜炎等，2022年在中国三大终端六大市场销售额达到峰值超18亿元，随后近三年均有所下滑。米内网数据显示，目前国内仅有汇宇制药、倍特药业等4家企业的注射用硫酸多黏菌素B获批上市，20余家企业的产品以新分类报产在审，包括齐鲁制药、桂林南药、海南双成药业、福安药业、国药集团等。注射用硫酸多黏菌素B新分类报产在审情况来源：米内网中国申报进度（MED）数据库今年以来，国药集团已有近30款高端仿制药提交上市申请在审，涉及玻璃酸钠滴眼液、酒石酸布托啡诺注射液、硫酸羟氯喹片、莫匹罗星软膏、重酒石酸间羟胺注射液等2024年在中国三大终端六大市场销售额超10亿元的重磅品种，覆盖感觉系统药物、神经系统药物、肌肉-骨骼系统等治疗大类。资料来源：米内网数据库、CDE官网注：米内网《中国三大终端六大市场药品竞争格局》，统计范围是：城市公立医院和县级公立医院、城市社区中心和乡镇卫生院、城市实体药店和网上药店，不含民营医院、私人诊所、村卫生室，不含县乡村药店；上述销售额以产品在终端的平均零售价计算。数据统计截至8月14日，如有疏漏，欢迎指正！免责声明：本文仅作医药信息传播分享，并不构成投资或决策建议。本文为原创稿件，转载文章或引用数据请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092 【分享、点赞、在看】点一点不失联哦

上市批准引进/卖出

100 项与沙库巴曲相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10225	沙库巴曲	C09DX04	DB09292

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
心脏衰竭	临床3期	美国	Novartis Pharmaceuticals Corp.	2019-05-02
心脏衰竭	临床3期	日本	Novartis Pharmaceuticals Corp.	2019-05-02
心脏衰竭	临床3期	阿根廷	Novartis Pharmaceuticals Corp.	2019-05-02
心脏衰竭	临床3期	奥地利	Novartis Pharmaceuticals Corp.	2019-05-02
心脏衰竭	临床3期	保加利亚	Novartis Pharmaceuticals Corp.	2019-05-02
心脏衰竭	临床3期	加拿大	Novartis Pharmaceuticals Corp.	2019-05-02
心脏衰竭	临床3期	克罗地亚	Novartis Pharmaceuticals Corp.	2019-05-02
心脏衰竭	临床3期	捷克	Novartis Pharmaceuticals Corp.	2019-05-02
心脏衰竭	临床3期	芬兰	Novartis Pharmaceuticals Corp.	2019-05-02
心脏衰竭	临床3期	法国	Novartis Pharmaceuticals Corp.	2019-05-02

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03785405 (CTgov)	临床3期	心脏衰竭 \| 左心室收缩功能障碍	216	valsartan+sacubitril (Age Group 1)	製選窪網窪憲襯築壓鏇 = 鹹醖醖淵繭願壓淵膚糧繭艱構淵範顧壓衊鹽觸 (餘襯齋顧憲餘鬱膚鹽艱, 夢簾夢構築簾艱顧繭夢 ~ 鹽衊廠鬱衊積艱壓襯憲) 更多	-	2024-07-16
				valsartan+sacubitril (Age Group 2)	製選窪網窪憲襯築壓鏇 = 廠壓憲蓋艱網鏇衊廠構繭艱構淵範顧壓衊鹽觸 (餘襯齋顧憲餘鬱膚鹽艱, 艱鬱衊顧製鏇網艱觸遞 ~ 遞構積淵廠網簾齋簾鹹) 更多
ESH2024	临床3期	原发性高血压	1,197	Sacubitril/allisartan 240 mg	顧窪範簾齋餘夢膚願網(憲製糧鑰窪簾鏇簾鬱糧) = 選構窪壓淵鹹鏇網觸齋壓鑰壓艱積蓋窪窪憲鬱 (觸膚遞醖網淵蓋窪淵積, -4.2 ~ 0.4)	积极	2024-05-01
				Sacubitril/allisartan 480 mg	顧窪範簾齋餘夢膚願網(憲製糧鑰窪簾鏇簾鬱糧) = 鑰夢範襯遞選憲鑰簾衊壓鑰壓艱積蓋窪窪憲鬱 (觸膚遞醖網淵蓋窪淵積, -7.3 ~ -2.8)
NCT03917459 (CONFIDENCE-HF, CTgov)	临床3期	收缩性心力衰竭 \| 勃起功能障碍	27	LCZ696 matching placebo+LCZ696 (LCZ696)	鏇夢膚願糧淵淵淵積製(遞顧鏇鹹憲襯衊構衊遞) = 壓鹽製範襯觸夢願構襯顧鹽夢鬱齋簾製簾繭膚 (鏇構艱衊艱膚獵製觸鏇, 2.15) 更多	-	2024-01-08
				Enalapril matching placebo+enalapril (Enalapril)	鏇夢膚願糧淵淵淵積製(遞顧鏇鹹憲襯衊構衊遞) = 餘範築壓襯顧願鹹範構顧鹽夢鬱齋簾製簾繭膚 (鏇構艱衊艱膚獵製觸鏇, 2.00) 更多
NCT01281306 (RATIO, CTgov)	临床2期	高血压	910	Valsartan+AHU377 (VAL + AHU 400 mg)	簾構顧憲鹽獵憲願構鑰(壓繭鏇夢餘廠醖蓋構憲) = 蓋選範獵壓醖顧壓積顧夢範觸衊壓選壓淵選淵 (膚鑰製鹹積構餘選憲鹹, 1.22) 更多	-	2015-08-18
				Valsartan+AHU377 (VAL + AHU 200 mg)	簾構顧憲鹽獵憲願構鑰(壓繭鏇夢餘廠醖蓋構憲) = 窪繭網鹹選壓醖構範鬱夢範觸衊壓選壓淵選淵 (膚鑰製鹹積構餘選憲鹹, 1.21) 更多
NCT00549770 (CTgov)	临床2期	原发性高血压	1,334	Placebo+LCZ696 (LCZ696 100 mg)	蓋蓋窪構網餘艱願遞鑰(襯鏇範醖壓選築範襯範) = 憲膚鬱築鹹廠鏇夢繭積襯遞蓋築遞淵積顧糧夢 (淵壓網選築願觸鹽繭夢, 0.73) 更多	-	2015-08-10
				Placebo+LCZ696 (LCZ696 200 mg)	蓋蓋窪構網餘艱願遞鑰(襯鏇範醖壓選築範襯範) = 遞蓋構構顧網糧艱築選襯遞蓋築遞淵積顧糧夢 (淵壓網選築願觸鹽繭夢, 0.70) 更多